SCHEMBL6530167

SCHEMBL6530167

O=C(Cc1ccccc1C(=O)O)Cc1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.59
ALDH1A1 P00352 5/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.53
KDM4E B2RXH2 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
HMGB1 P09429 1/20 0.48
HPGD P15428 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CA9 Q16790 1/20 0.48
NAPRT Q6XQN6 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
BCAT2 O15382 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12013904 0.88 FOLH1 (0.52) FOLH1ALDH1A1ALOX15TSHRKDM4E
2-Carboxybenzeneacetic Acid SCHEMBL1891118 0.86 AKR1B1 (0.61) FOLH1ALDH1A1ALOX15TSHRKDM4E
2-Carboxybenzeneacetic Acid SCHEMBL27477 0.86 AKR1B1 (0.61) FOLH1ALDH1A1ALOX15TSHRKDM4E
SCHEMBL9464875 0.85 FOLH1 (0.49) FOLH1ALDH1A1ALOX15TSHRKDM4E
SCHEMBL28332847 0.85 FOLH1 (0.49) FOLH1ALDH1A1ALOX15TSHRKDM4E
SCHEMBL29158552 0.85 FOLH1 (0.53) FOLH1ALDH1A1ALOX15TSHRKDM4E
2-Carboxybenzeneacetic Acid SCHEMBL3975685 0.84 BCAT2 (0.59) FOLH1ALDH1A1ALOX15TSHRKDM4E
SCHEMBL11443185 0.84 FOLH1 (0.57) FOLH1ALDH1A1ALOX15TSHRKDM4E
2-Carboxybenzeneacetic Acid SCHEMBL4828304 0.84 BCAT2 (0.59) FOLH1ALDH1A1ALOX15TSHRKDM4E
SCHEMBL6824473 0.83 KDM4E (0.53) FOLH1ALDH1A1ALOX15TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115298180-B Compounds for treating or inhibiting recurrence of acute myeloid leukemia 日本理化学研究所 2025-06-10 CN disclosed
US-20050043411-A1 Process for preparing homophthalate derivatives TJGEL, LLC 2005-02-24 US disclosed
US-6797838-B2 Process for preparing homophthalate derivatives ILEX PRODUCTS, INC. 2004-09-28 US disclosed
EP-1404662-A2 PROCESS FOR PREPARING ISOCOUMARINS Ilex Products, Inc. (US) 2004-04-07 EP disclosed
US-20040024240-A1 Process for preparing homophthalate derivatives GENZYME CORPORATION 2004-02-05 US disclosed
US-6664401-B2 Reacting a isochroman-1,3-dione with a carbonyl compound whose carbonyl group is substituted with an acyl activating group, in the presence of a base and a solvent; use making anticancer agents for example ILEX PRODUCTS, INC. 2003-12-16 US disclosed
US-20030105340-A1 Process for preparing isocoumarins GENZYME CORPORATION 2003-06-05 US disclosed
WO-2003004486-A2 PROCESS FOR PREPARING ISOCOUMARINS ILEX PRODUCTS, INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105340-A1 Process for preparing isocoumarins DHPS, IDH2, IDH1 FOLH1 2953/4885ALDH1A1 1178/4885ALOX15 997/4885
US-20050043411-A1 Process for preparing homophthalate derivatives HPD, HAAO, PAH FOLH1 1472/4885ALDH1A1 669/4885ALOX15 2246/4885
US-20040024240-A1 Process for preparing homophthalate derivatives HPD, HAAO, PAH FOLH1 1472/4885ALDH1A1 669/4885ALOX15 2246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.